Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
02:14pm, Wednesday, 18'th Feb 2026
CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Should You Buy Shares of CRISPR Therapeutics in February?
09:53am, Wednesday, 18'th Feb 2026
The company could finally be ready to deliver on years of promise.
CRISPR Therapeutics Q4: The Elite Time To Buy Is In 2027
11:49am, Tuesday, 17'th Feb 2026
CRISPR Therapeutics AG is commercially validated with CASGEVY but remains financially unproven and operates at a loss despite strong cash reserves. Incremental buying is attractive now for patient CRS
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 17'th Feb 2026
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026
03:10pm, Friday, 13'th Feb 2026
Buying biotech stocks is a great way to add growth to your portfolio. This particular player won approval for its first product a couple of years ago, proving the strength of its game-changing technol
Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss)
02:02pm, Friday, 13'th Feb 2026
CRISPR Therapeutics' fourth quarter was relatively disappointing. As a biotech start-up still in its infancy though, these early quarterly numbers don't mean much.
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
01:45pm, Friday, 13'th Feb 2026
Casgevy, the company's gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia, generated $54 million in fourth-quarter revenue and $116 million for the full year.
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates
11:05am, Friday, 13'th Feb 2026
CRISPR Therapeutics posts a wider Q4 loss and revenues miss, but Casgevy sales climb, with label expansion plans and pipeline updates ahead.
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue Estimates
07:01pm, Thursday, 12'th Feb 2026
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.37 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $0.44 per share a year ago.
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
04:30pm, Thursday, 12'th Feb 2026
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. “As
Jones Financial Companies Lllp Buys 14,948 Shares of CRISPR Therapeutics AG $CRSP
06:14am, Monday, 09'th Feb 2026
Jones Financial Companies Lllp boosted its stake in CRISPR Therapeutics AG (NASDAQ: CRSP) by 50.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund o
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
10:01am, Friday, 06'th Feb 2026
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
11:01am, Tuesday, 03'rd Feb 2026
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?
09:32am, Tuesday, 03'rd Feb 2026
CRISPR Therapeutics heads into Q4 earnings with rising Casgevy sales, collaboration revenues from Vertex, and a history of beating estimates.
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
06:51pm, Monday, 02'nd Feb 2026
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $51.31, denoting a +2.7% move from the preceding trading day.
